Obesity-drug developer BioAge Labs Inc. gained about 20% after its initial public offering on Thursday, while natural-gas ...

California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.

BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...

BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...

The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

BioAge Labs (BIOA), which is developing a drug to augment popular weight-loss medications such as Wegovy and Zepbound, has upsized its proposed IPO. Read more here.

BioAge Labs, Inc BIOA IPO will take place September, 26 on the NASDAQ exchange under the ticker BIOA. The company is offering ...

Texas-based Barnett Shale driller prices below the estimated range, while obesity-drug developer BioAge prices midrange ahead ...

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of ...